Y-Intercept (HK)’s Damora Therapeutics DMRA Stock Holding History

Y-Intercept (HK)’s Portfolio DMRA Stock Details DMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-7,921	Closed	-$205K	–	1886
2026 Q1	$205K	Buy	+7,921	New	+$204K	﹤0.01%	1439

Other funds holding DMRA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Jupiter Topco New York $245B AUM

RCP

Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

Y-Intercept (HK)'s DMRA Position: Q2 2026 in Review

Y-Intercept (HK) sold out of Damora Therapeutics (DMRA) in Q2 2026, closing a stake of 7,921 shares — an estimated $205K sold.

Y-Intercept (HK) first reported a position in DMRA in Q1 2026 and held it in 1 quarter. The position peaked at $205K in Q1 2026. 104 funds tracked by Wall St. Rank hold DMRA as of Q2 2026.

Y-Intercept (HK) reported no remaining Damora Therapeutics position as of Q2 2026 after selling out during the quarter.
Y-Intercept (HK) sold 7,921 Damora Therapeutics shares in Q2 2026, an estimated $205K.
Y-Intercept (HK) first reported a position in Damora Therapeutics in Q1 2026 and held it in 1 quarter.
Y-Intercept (HK)'s Damora Therapeutics position peaked at $205K in Q1 2026.
104 funds tracked by Wall St. Rank held Damora Therapeutics as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.